DXCM Announcement: Contact Kessler Topaz Meltzer & Check, LLP About the Securities Fraud Class Action Lawsuit Filed Against DexCom, Inc. (DXCM)

Core Viewpoint - A securities class action lawsuit has been filed against DexCom, Inc. for alleged misleading statements and undisclosed material changes to its glucose monitoring systems during the specified class period from January 8, 2024, to September 17, 2025 [1][3]. Group 1: Allegations Against DexCom - The complaints allege that DexCom made unauthorized design changes to its G6 and G7 continuous glucose monitoring systems, which compromised their reliability and posed health risks to users [3]. - It is claimed that DexCom overstated the enhancements and reliability of the G7 device, downplaying the severity of issues related to adulterated devices [3]. - The allegations suggest that these actions increased DexCom's exposure to regulatory scrutiny and potential legal, reputational, and financial harm [3]. Group 2: Legal Process and Investor Actions - Investors who suffered losses can seek to be appointed as lead plaintiffs by December 26, 2025, or may choose to remain absent class members [4]. - The lead plaintiff will represent the interests of all class members and select legal counsel for the case [4]. - Kessler Topaz Meltzer & Check, LLP encourages affected investors to contact them for more information regarding the lawsuit [5].